ADPT (Adaptive Biotechnologies) Tariff Resilience Score: 7/10 (As of Jul. 01, 2026)


ADPT Adaptive Biotechnologies Corp ADPT
67 GF Score
Price $22.37
GF Value $10.06
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Adaptive Biotechnologies Tariff Resilience Score?

Adaptive Biotechnologies ADPT +4.34% 67 Tariff Resilience Score is 7 as of Jul. 01, 2026. GuruFocus rates ADPT with a GF Score™ of 67/100 and a GF Value™ of $10.06 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 215 Medical Diagnostics & Research companies, Adaptive Biotechnologies ranks better than 95.81% on this metric.

Adaptive Biotechnologies has the Tariff Resilience Score of 7, which implies that the company might have Highly Resilient.

Adaptive Biotechnologies has Adaptive Biotechnologies has a moderate exposure to tariffs due to its reliance on global suppliers for specialized biotech components. However, its primary market is the U.S., and it has some pricing power and alternative supplier options, which mitigate risks.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Adaptive Biotechnologies might have Highly Resilient.

Adaptive Biotechnologies  (NAS:ADPT) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Adaptive Biotechnologies Tariff Resilience Score Related Terms

ADPT vs GRAL, WGS, RDNT: Tariff Resilience Score Comparison

For the Diagnostics & Research subindustry, Adaptive Biotechnologies's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Adaptive Biotechnologies Tariff Resilience Score vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Adaptive Biotechnologies's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Adaptive Biotechnologies's Tariff Resilience Score falls into.


ADPT
67GF Score
Adaptive Biotechnologies Corp ADPT
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 7 mean?
Adaptive Biotechnologies (ADPT) has a Tariff Resilience Score of 7 as of Jul. 01, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Adaptive Biotechnologies ranks #9 out of 215 companies in the Medical Diagnostics & Research industry, placing it in the top 4.2%.
Is Adaptive Biotechnologies' Tariff Resilience Score too high?
Adaptive Biotechnologies' current Tariff Resilience Score is 7. Based on the distribution chart, Adaptive Biotechnologies ranks #9 out of 215 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Adaptive Biotechnologies has a GF Score™ of 67/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Adaptive Biotechnologies' Tariff Resilience Score compare to GRAL and WGS?
According to the Medical Diagnostics & Research industry distribution chart, Adaptive Biotechnologies ranks #9 out of 215 companies for Tariff Resilience Score. This places Adaptive Biotechnologies in the top 4% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Medical Diagnostics & Research company?
A good Tariff Resilience Score depends on the Medical Diagnostics & Research industry context. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. Adaptive Biotechnologies's current Tariff Resilience Score is 7. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Adaptive Biotechnologies stock overvalued right now?
Based on GuruFocus' analysis, Adaptive Biotechnologies (ADPT) is currently considered Significantly Overvalued. The stock's GF Value™ is $10.06, compared to a current price of $22.37 — trading 122.4% above its estimated fair value. The current Tariff Resilience Score is 7. Adaptive Biotechnologies' overall GF Score™ is 67/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Adaptive Biotechnologies (ADPT), the current Tariff Resilience Score is 7 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Adaptive Biotechnologies (ADPT) Overvalued in 2026?

Based on GuruFocus' analysis, Adaptive Biotechnologies stock appears to be overvalued. The current stock price of $22.37 is trading 122.4% above its estimated GF Value™ of $10.06. GuruFocus considers Adaptive Biotechnologies to be Significantly Overvalued.

Key valuation signals for ADPT:

  • Tariff Resilience Score: 7
  • GF Value™: $10.06 vs. price of $22.37 (122.4% above fair value)
  • GF Score™: 67/100 with 5 warning signs

No single metric tells the full story. See the ADPT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Adaptive Biotechnologies Business Description

Other Exchanges 1HM:Germany
Address 1165 Eastlake Avenue East, Seattle, WA, USA, 98109
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.
67GF Score

Get the complete analysis for ADPT

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$22.37
Price
$10.06
GF Value